Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK Interaction of Empagliflozin and Ezetimibe/Rosuvastatin in Healthy Adults
NCT06578676Phase 1Recruiting
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and dyslipidemia comparing Empagliflozin Sequence with Ezetimibe/Rosuvastatin Sequence (2 arms). Primary endpoints: Maximum Plasma Concentration at Steady State and Area Under the Concentration-Time Curve over the Dosing Interval at Steady State. Started Jun 2024; status: recruiting.
02
Drugs
empagliflozinezetimiberosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT06578676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578676.